Sex, drugs, and trial design: Sex influences the heart and drug responses

Journal of Clinical Investigation

Volumn 124, Issue 6, 2014, Pages 2375-2377

  Murphy, Elizabeth ^a   Steenbergen, Charles ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; ZOLPIDEM;

CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; HEART; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART HYPERTROPHY; HEART RIGHT VENTRICLE FAILURE; HEART STRESS; HUMAN; LIGATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; STUDY DESIGN; SYSTOLIC HEART FAILURE;

ANIMALS; ESTROGENS; FEMALE; HEART DISEASES; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS;

EID: 84902122722     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI76262     Document Type: Review

References (14)

1. Lee DI, Kass DA. Phosphodiesterases and cyclic GMP regulation in heart muscle. Physiology (Bethesda). 2012;27(4):248-258.
2. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999;83(5 A):3C-12C.
3. Vandenwijngaert S, et al. Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling. PLoS One. 2013;8(3):e58841.
4. Nagayama T, et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol. 2009;53(2):207-215.
5. Takimoto E, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11(2):214-222.
6. Kim KH, et al. Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits of ventricular remodeling and exercise capacity. Circulation. 2012;125(11):1390-1401.
7. Pokreisz P, et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation. 2009;119(3):408-416.
8. Shan X, Quaile MP, Monk JK, French B, Cappola TP, Margulies KB. Differential expression of PDE5 in failing and nonfailing human myocardium. Circ Heart Fail. 2012;5(1):79-86.
9. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebocontrolled study. Circ Heart Fail. 2011;4(1):8-17.
10. Redfield MM, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309(12):1268-1277.
11. Greiten LE, Holditch SJ, Arunachalam SP, Miller VM. Should there be sex-specific criteria for the diagnosis and treatment of heart failure? J Cardiovasc Transl Res. 2014;7(2):139-155.
12. Farkas RH, Unger EF, Temple R. Zolpidem and driving impairment - identifying persons at risk. N Engl J Med. 2013;369(8):689-691.
13. Murphy E. Estrogen signaling and cardiovascular disease. Circ Res. 2011;109(6):687-696.
14. Sasaki H, et al. PDE5 inhibitor efficacy is estrogen dependent in female heart disease. J Clin Invest. 2014;124(6):2464-2471.